COMMUNIQUÉS West-GlobeNewswire

Cullinan Therapeutics Receives FDA Orphan Drug Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia
19/05/2026
Orphan Drug Designation underscores the potential of CLN-049, a novel FLT3xCD3 T cell engager, to address significant unmet need in AML CAMBRIDGE, Mass., May 19, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. ( [...]
Korro Selects KRRO-111 as Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
19/05/2026
Potential best-in-class therapeutic delivered subcutaneously (GalNAc-conjugated oligonucleotide) for a debilitating genetic condition impacting both the liver and lungs Demonstrated >90% editing of SERPINA1 [...]
Lexeo Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
19/05/2026
NEW YORK, May 19, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced that [...]
OKYO Expands Scientific Advisory Board with the Appointment of International Expert Marta Sacchetti, MD, PhD
19/05/2026
Dr. Sacchetti brings international expertise in clinical and translational research on ocular inflammatory and degenerative disease OKYO’s introduction to the broader ophthalmology community at ASCRS drove strong [...]
Medicenna Announces the Finalization of the Terms of its Public Offering of Securities
19/05/2026
Base shelf prospectus is accessible, and prospectus supplement will be accessible within two business days on SEDAR+ 1 TORONTO and HOUSTON, May 19, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or [...]
Tiziana Announces New Positive Clinical Data for Intranasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis
19/05/2026
Favourable trends seen in stability of disability and clinically meaningful improvements in fatigue. BOSTON, May 19, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA ) ("Tiziana"), a biotechnology [...]
AdrenoMed Highlights Need for Personalized Therapies in Septic Shock Amid New Sepsis Guidelines and U.S. Policy Initiative
19/05/2026
Hennigsdorf / Berlin (Germany), May 19, 2026 (GLOBE NEWSWIRE) -- Press Release AdrenoMed Highlights Need for Personalized Therapies in Septic Shock Amid New Sepsis Guidelines and U.S. Policy Initiative 2026 Surviving [...]
GenoSafe advances CLIA pathway for transatlantic ATMP development
19/05/2026
GenoSafe advances CLIA pathway for transatlantic ATMP development CLIA registration enables GenoSafe to support testing of samples from U.S.-based patients enrolled in clinical trials. This milestone strengthens [...]
HEPHAISTOS-Pharma appoints Stephan Braun as Chief Medical Officer to lead clinical development strategy
19/05/2026
HEPHAISTOS-Pharma appoints Stephan Braun as Chief Medical Officer to lead clinical development strategy Former ImCheck Therapeutics clinical leader joins HEPHAISTOS-Pharma as the company prepares to advance its lead [...]
FEATOL Introduces Ergonomic Wrist Support for Modern Repetitive Strain Challenges
19/05/2026
NEW YORK, May 19, 2026 (GLOBE NEWSWIRE) -- FEATOL has introduced the FEATOL 2 Pack Carpal Tunnel Wrist Brace, a wrist support solution for daily stabilization, pain relief, and recovery support. The brace is made for [...]
Anaveon Strengthens Leadership Team with Appointments of Eric Zanelli as Chief Scientific Officer and Jill Jene as Chief Business Officer
19/05/2026
BASEL, Switzerland, May 19, 2026 (GLOBE NEWSWIRE) -- Anaveon, a late-stage biotechnology company pioneering precision biologics to reprogram the immune system for the treatment of autoimmune and inflammatory diseases, [...]
Transactions in connection with share buy-back program
19/05/2026
Company announcement no. 17 - 26 19 May 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as described in company [...]
Mestag Therapeutics Announces the First Patient Dosed with MST-0312 in the Phase I STARLYS Trial
19/05/2026
-- STARLYS trial to evaluate the potential of MST-0312, a targeted lymphotoxin-beta (LTBR) agonist bispecific antibody, as a novel therapeutic strategy for the treatment of solid tumors. -- Study to evaluate tertiary [...]
ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026
19/05/2026
EINDHOVEN, The Netherlands, May 19, 2026 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD – US ADR: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, function, and independence [...]
Unaudited Preliminary Results for the Year Ended December 31, 2025
19/05/2026
LONDON and PHILADELPHIA, May 19, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, “the Company”, “Avacta”), a clinical stage biopharmaceutical company developing pre|CISION, a tumor-activated oncology delivery [...]
Khondrion Announces First Patient Dosed in Phase II Study Targeting Debilitating Post-COVID Fatigue
19/05/2026
SON4PEM trial advances development of sonlicromanol, aiming to address chronic fatigue in Post-COVID patients with post-exertional malaise NIJMEGEN, The Netherlands, May 19, 2026 (GLOBE NEWSWIRE) -- Khondrion today [...]
SERB Pharmaceuticals to acquire European and MENA rights to Idefirix® (imlifidase) from Hansa Biopharma for €115 million
19/05/2026
BRUSSELS, May 19, 2026 (GLOBE NEWSWIRE) -- SERB Pharmaceuticals (“SERB”) and Hansa Biopharma AB (“Hansa”) (Nasdaq Stockholm: HNSA) today announced that they have entered into an agreement under which SERB will acquire [...]
Roche to present new data at ASCO 2026, reinforcing giredestrant's potential to transform the treatment paradigm in early breast cancer
19/05/2026
New giredestrant data from the lidERA study on its potential as a new standard of care for adjuvant ER-positive breast cancer across all menopausal stages Primary results from the persevERA study on the numerical [...]
Rapid Nutrition Advances Finalization of Australian Flagship Initiative
19/05/2026
LONDON, May 19, 2026 (GLOBE NEWSWIRE) -- Rapid Nutrition PLC (Euronext Growth: ALRPD ), a global HealthTech company focused on evidence-based nutrition brands, is pleased to provide an update regarding its Australian [...]

Pages